Press Releases

Botanical Solution Inc.innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has entered into a Partnership Agreement with Croda Pharma to build a robust, scalable and truly sustainable supply chain and deliver kilogram-quantities of QS-21 to the pharmaceutical industry.BSI and Croda Pharma are announcing this Partnership Agreement at the World Vaccine and Immunotherapy Congress West Coast 2022 in San Diego this

ERS Genomics Limited is pleased to announce a new license agreement with Cosmo Bio. This is a non-exclusive license agreement granting Japan's Cosmo Bio access to the ERS CRISPR/Cas9 patent portfolio. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Over 100 patents are held worldwide.Eric Rhodes, CEO at ERS had the following statement: "CRISPR/Cas

WuXi STA, a subsidiary of WuXi AppTec, today announced a new parenteral formulation manufacturing line has started operation at the drug product site in Wuxi city, China. It is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units. This expansion demonstrates the company’s continuous commitment to enhance its injectable drug product platform. This new line features a fully automatic vial

JB Pharma, one of the fastest growing pharmaceutical companies in India, today, has announced that it has received final approval from USFDA for its Abbreviated New Drug Application (ANDA), Venlafaxine Extended Release Tablets 37.5 mg, 75 mg, 150 mg and 225 mg. This product is based on OROS (Osmotic Controlled Release Oral Delivery System) technology, an advanced and precision controlled release mechanism – an area where JB has seen success with 3 products already in the US ma

Focused on demonstrating a new shape of the pharmaceutical manufacturing in the post COVID era, CPHI & PMEC India 2022, organized by Informa Markets in India, commenced today at the India Expo Centre, Greater Noida, Delhi – NCR. The co-located shows provided a unique opportunity to all the stakeholders to discuss the entire range of pharma machinery, analytical instruments, laboratory technologies and equipment’s, ancillaries, ingredients and more in a hybrid format.

TrialSpark announced today the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences. The Libertas Bio pipeline now includes global rights to gusacitinib, an oral Phase 3-ready dual JAK/SYK inhibitor in development for chronic hand eczema, and ASN008, a Phase 2-ready topical sodium channel blocker in development for pruritus associated with atopic dermatitis. Libertas Bio will continue the development of th

The Fourth Assembly of Chinese Physicians in the Service of Humanity  has launched its first international chapter, inviting experts, doctors and public welfare professionals from the UK , Norway, Czech Republic and other countries to share their ideas on evidence-based medicine .This year, CPAH was held online and offline on November 4-5, with the theme  Cohesion and Co-Construction: Physicians' Responsibilities for Wellness in Healthcare . The online internati

Biocytogen Pharmaceuticals Co., Ltd. today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfr

Ascletis Pharma Inc. announces today that the Investigational New Drug  application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease for COVID-19, has been accepted by China National Medical Products Administration. In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated much higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, PBI-0451 and EDP-235. ASC11 remains potent antiviral ac

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces that it has opened its new facilities in York Science Park, UK, that will enable it to meet the increasing demand for Optimer technology. The eminent neuroscience researcher Baroness Susan Greenfield opened the new 18,000 sqft site on November 25th with York Central’s MP Rachel Maskell also present at the event. The visitors received a tour of the new pr